Palisade Bio Launches PALI-2108 Study to Combat Crohn’s Disease
Exciting Developments in Crohn’s Disease Treatment Today marks a pivotal point as Palisade Bio, Inc. (NASDAQ: PALI), a dynamic clinical-stage biopharmaceutical firm, undertakes a groundbreaking step in medical research by announcing the commencement of patient dosing in their Phase 1b clinical trial. This study is focused on PALI-2108, a novel therapeutic designed...
Continue Reading